TCM
VKTX icon

Triumph Capital Management’s Viking Therapeutics VKTX Stock Holding History

Triumph Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.9K Buy
+100
New +$3.23K ﹤0.01% 1434

Other funds holding VKTX

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
RFM
Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Triumph Capital Management's VKTX Position: Q2 2026 in Review

Triumph Capital Management opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 100 shares worth $3.9K. The stake represents ﹤0.01% of the portfolio and ranks #1434 among its holdings.

59 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Triumph Capital Management held 100 shares of Viking Therapeutics worth $3.9K as of Q2 2026.
  • Viking Therapeutics was a new Triumph Capital Management position in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1434 holding.
  • 59 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.